GR2002 injection
Sponsors
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Conditions
AsthmaAtopic Dermatitis
Phase 1
The Study of Single Dose Administration of GR2002 Injection in Chinese Health Volunteers
CompletedNCT05954611
Start: 2023-06-16End: 2024-01-02Updated: 2024-08-22
A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.
NCT06175143
Start: 2023-12-31End: 2024-10-31Target: 40Updated: 2023-12-18